A case report of low-grade appendiceal mucinous neoplasm in perforated appendicitis: literature review, acute surgery and later additional HIPEC treatment to prevent pseudomixoma peritonei

被引:0
作者
Alessandrini, Sofia [1 ]
Di Schiena, Fabiola [1 ]
Di Lieto, Giulia [1 ]
Ungania, Serena [1 ]
Mandarano, Martina [2 ]
Del Sordo, Rachele [2 ]
Evoli, Luca P. [3 ]
机构
[1] Univ Perugia, Sect Gen Surg, Dept Surg & Biochem Sci, Perugia, Italy
[2] Univ Perugia, Sect Anat Pathol & Histol, Dept Med & Surg, Perugia, Italy
[3] Santa Maria Misericordia Hosp, Sect Gen Surg, Perugia, Italy
来源
CHIRURGIA-ITALY | 2023年 / 36卷 / 03期
关键词
Appendiceal neoplasms; Hyperthermic intraperitoneal chemotherapy; Pseudomyxoma peritonei; COMPLETE TUMOR REMOVAL; PSEUDOMYXOMA PERITONEI; CYTOREDUCTIVE SURGERY; CLASSIFICATION; DIAGNOSIS; RECURRENCE; CONSENSUS; SURVIVAL; MARKERS;
D O I
10.23736/S0394-9508.22.05471-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
Low-grade appendiceal mucinous neoplasm (LAMN) accounts less than 0.5% of all gastrointestinal neoplasm. Early stage AMNs are usually incidentally diagnosed on a surgical specimen after appendectomy for acute appendicitis. In this study, we reported a 42-year-old female presented complaining right lower abdominal pain for 3 days. Abdominal US revealed inflamed appendix surrounded by ipo-anechoic area of 3 cm, with increased thickness of near ileus. Intraoperatively a fistula between appendix and terminal ileum was found; for that reason, a right hemicolectomy was performed. Histopathology indicated a low-grade appendiceal mucinous neoplasms (LAMNs). Four months later the patient underwent hyperthermic intraperitoneal chemotherapy (HIPEC) with C-mitomycin and Cisplatin and was followed up for 6 months with no disease progression, confirmed by CT scan. At present there is not a consensus about LAMNs treatment, due to the scarcity of cases. Consensus statement of the Peritoneal Surface Oncology Group published in 2020 seems to be the best guideline available nowadays; Recommendations are provided based on three Delphi voting rounds with GRADE-based questions amongst a panel of 80 worldwide PMP experts. Given the rarity of these pathologies, each clinical case and longer follow up are important. Appropriate surgery-based treatment followed by HIPEC could contribute to the improvement of prognosis and severe outcomes among these patients. In our opinion patients affected by LAMN should receive prophylactic HIPEC treatment in order to achieve the greatest survival benefit even if they run the risk of overtreatment.
引用
收藏
页码:157 / 163
页数:7
相关论文
共 28 条
  • [1] Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence
    Alexander-Sefre, F
    Chandrakumaran, K
    Banerjee, S
    Sexton, R
    Thomas, JM
    Cecil, T
    Moran, B
    [J]. COLORECTAL DISEASE, 2005, 7 (04) : 382 - 386
  • [2] Prognostic value of circulating tumor markers in patients with Pseudomyxoma Peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Baratti, Dario
    Kusamura, Shigeki
    Martinetti, Antonia
    Seregni, Ettore
    Laterza, Barbara
    Oliva, Daniela G.
    Deraco, Marcello
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (08) : 2300 - 2308
  • [3] Local Protocol for Management of Low-Grade Appendiceal Mucinous Neoplasm (LAMN)
    Boshnaq, Mohamed
    Toeima, Mohamed
    Hamade, Ayman
    Bagla, Nipin
    [J]. INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2020, 11 (03) : 355 - 359
  • [4] Carr N J., 2010, WHO Classification ofTumours of the Digestive System, P122
  • [5] Carr NJ, 2016, AM J SURG PATHOL, V40, P14, DOI 10.1097/PAS.0000000000000535
  • [6] Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Chua, Terence C.
    Moran, Brendan J.
    Sugarbaker, Paul H.
    Levine, Edward A.
    Glehen, Olivier
    Gilly, Francois N.
    Baratti, Dario
    Deraco, Marcello
    Elias, Dominique
    Sardi, Armando
    Liauw, Winston
    Yan, Tristan D.
    Barrios, Pedro
    Gomez Portilla, Alberto
    de Hingh, Ignace H. J. T.
    Ceelen, Wim P.
    Pelz, Joerg O.
    Piso, Pompiliu
    Gonzalez-Moreno, Santiago
    Van der Speeten, Kurt
    Morris, David L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) : 2449 - 2456
  • [7] Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei
    Delhorme, J. -B.
    Honore, C.
    Benhaim, L.
    Dumont, F.
    Dartigues, P.
    Dromain, C.
    Ducreux, M.
    Elias, D.
    Goere, D.
    [J]. EJSO, 2017, 43 (01): : 159 - 167
  • [8] FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei
    Dubreuil, Julien
    Giammarile, Francesco
    Rousset, Pascal
    Bakrin, Naoual
    Passot, Guillaume
    Isaac, Sylvie
    Glehen, Olivier
    Skanjeti, Andrea
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (09) : 1630 - 1637
  • [9] Unusual case of intraluminal cecal recurrence of a low grade appendiceal mucinous neoplasm (LAMN)-Case report and brief literature review
    Givalos, Nick
    Manolidis, Georgios
    Kochylas, Nikolaos
    Vrachni, Vasiliki
    Tsakona, Sofia
    Eftychiadis, Christos
    Vrachnos, Panos
    [J]. INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2018, 51 : 112 - 116
  • [10] Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment
    Govaerts, K.
    Lurvink, R. J.
    De Hingh, I. H. J. T.
    Van der Speeten, K.
    Villeneuve, L.
    Kusamura, S.
    Kepenekian, V
    Deraco, M.
    Glehen, O.
    Moran, B. J.
    [J]. EJSO, 2021, 47 (01): : 11 - 35